Ovarian Cancer

Home / Ovarian Cancer

Ovarian Cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual tumor. HIPEC increases concentrations of chemotherapy directly within the peritoneal cavity compared with the intravenous route and reduces the systemic side effects associated with prolonged adjuvant intraperitoneal exposure. Furthermore, hyperthermia increases tissue penetration and is synergistic with the therapeutic chemotherapy agents used. In ovarian cancer, evidence is building for its use in both primary and recurrent scenarios.”.

To read more about this study, click here.

A trial study conducted in participating centers in the Netherlands and Belgium and published in The New England Journal of Medicine, concluded that ” among patients with stage III epithelial ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone and did not result in higher rates of side effects”.  In this study 245 patients  were randomized between interval cytoreductive surgery alone and interval cytoreductive surgery with HIPEC (Hyperthermic Intraperitoneal Chemotherapy).The study found that patients who underwent cytoreductive surgery with HIPEC had a median overall survival of  45.7 months.

To read more about this study, view the abstract on the The New England Journal of Medicine.

Many of the cancers treated with HIPEC are diseases treated by multiple disciplines in medicine and surgery. It is important that patients discuss HIPEC therapy with their oncologists and surgeon who can guide their therapy appropriately. Sometimes a referral to a Surgical Oncologist or Gynecological Oncologist performing HIPEC is helpful and necessary early at the time of diagnosis. These doctors can help determine if a patient can benefit from HIPEC and then formulate a comprehensive treatment plan.

HIPEC for Ovarian Cancer with Dr. Bagaria

Dr. Teresa Diaz Montes

Dr. Dennis Chi: What Ovarian Cancer Patients Should Know

Dr. David Bartlett discusses the treatment of ovarian cancer with HIPEC

Patient Story: HIPEC FOR OVARIAN CANCER

Dr. Armando Sardi: HIPEC Treatment of Late Stage Abdominal Cancer

VCU Massey Cancer Center now offering HIPEC for advanced abdominal cancers

HIPEC Treatment for Ovarian Cancer - Drs. Armando Sardi and Teresa Diaz-Montes - Mercy

Dr. Lewin on the Addition of HIPEC to Interval Cytoreductive Surgery in Ovarian Cancer

Podcast: HIPEC in Gynecologic Cancers by Dr. Robert DeBernardo, MD

Schedule a Conversation with a Surgeon

Would you like to browse our full surgeon database and locate a Surgical Oncologist/Gynecological Oncologist in your area?

Cancer Treatment Centers of America Offers Heated Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for Ovarian Cancer Patients, June 20, 2019

In March, the National Comprehensive Cancer Network (NCCN) released updated guidelines stating that Heated Intraperitoneal Chemotherapy (HIPEC) using the chemotherapy drug cisplatin can be considered with debulking surgery for stage III epithelial ovarian cancer patients. The guidelines, and the research supporting them, show that HIPEC has gained recognition as a promising and innovative procedure for an advanced and complex disease.

To read more about this study, read the full article on Yahoo News.

HIPEC Combo Doubles PFS in Advanced Ovarian Cancer — Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study

by Charles Bankhead, Senior Editor, MedPage Today

Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.

Median progression-free survival (PFS) doubled from 11 months with cisplatin alone to 22.2 months with the addition of paclitaxel. A similar difference existed for the proportion of patients who remained recurrence free at 12 months.

The improvement occurred with no adverse impact on complications, length of hospitalization, or discharge status, Laura Chambers, DO, of the Cleveland Clinic, reported during the virtual Society of Gynecologic Oncology annual meeting…

Read the full article on MedPage Today

Patients Share Their Stories

Dena’s Story

Dena’s Story

Dena Svoboda, 56, never expected a bad case of acid reflux would turn out to be cancer. “I thought it...

Read More
Julie’s Story

Julie’s Story

Julie Khoury, was treated with HIPEC during surgery to treat Ovarian Cancer. She is a Patient of Dr. Shanel Bhagwandin of...

Read More